Biondo Investment Advisors LLC Purchases 2,688 Shares of Johnson & Johnson $JNJ

Key Points

• Biondo Investment Advisors LLC increased its stake in Johnson & Johnson by 4.6%, purchasing an additional 2,688 shares, raising its total holdings to 61,362 shares valued at $10.18 million.
• Johnson & Johnson reported a net margin of 25% and revenue of $23.74 billion for the last quarter, exceeding analyst estimates and signaling a 5.8% increase year-over-year.
• The company declared a quarterly dividend of $1.30 per share, which will be paid on September 9th, representing an annualized dividend of $5.20 and a yield of 2.9%.

Biondo Investment Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 61,362 shares of the company's stock after acquiring an additional 2,688 shares during the period. Johnson & Johnson comprises approximately 1.4% of Biondo Investment Advisors LLC's holdings, making the stock its 29th biggest holding. Biondo Investment Advisors LLC's holdings in Johnson & Johnson were worth $10,176,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC increased its holdings in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the last quarter. Topsail Wealth Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $369,000. Voya Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 6.0% in the 4th quarter. Voya Financial Advisors Inc. now owns 4,998 shares of the company's stock valued at $716,000 after purchasing an additional 282 shares in the last quarter. Finally, Cheviot Value Management LLC lifted its holdings in Johnson & Johnson by 9.8% during the 4th quarter. Cheviot Value Management LLC now owns 155,318 shares of the company's stock worth $22,462,000 after buying an additional 13,823 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on JNJ shares. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Barclays increased their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded up $0.1680 during mid-day trading on Friday, reaching $179.0980. The stock had a trading volume of 9,523,149 shares, compared to its average volume of 8,657,504. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm's 50 day simple moving average is $163.48 and its 200 day simple moving average is $159.30. The firm has a market cap of $431.33 billion, a PE ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.